General contact

Main switchboard
Switzerland

+41 61 324 11 11
+41 61 324 80 01
Monday - Friday,
8:30 a.m. - 5:00 p.m. GMT+1

US switchboard

+1 862 778 21 00
Monday - Friday,
8:30 a.m. - 5:00 p.m. EST

Media

Global Media Relations
Eric Althoff
Basel, Switzerland

+41 61 324 7999

Investors

Investor Relations
Switzerland

Monday - Friday,
8:30 a.m. - 5:30 p.m. GMT+1
(Central European Time)

Reporting side effects

Report a suspected side effect (also known as an adverse event) related to a Novartis Pharmaceutical drug or a Novartis Vaccine.

Reporting side effects

pane 4 content

Product sales

Our complementary healthcare businesses address the changing needs of patients and societies worldwide. With innovative pharmaceuticals at the core, we are also a global leader in eye care and generics products.

Read more about the 2014 sales of our top 20 pharmaceutical products in the table below.

Product Full Year 2014 Product Sales Business franchise
USD m % change (USD)
Glivec 4,746 1% Oncology
Gilenya 2,477 28% Neuroscience
Lucentis 2,441 2% Ophthalmics
Diovan/Co-Diovan 2,345 -33% Primary care
Sandostatin 1,650 4% Oncology
Afinitor/Votubia 1,575 20% Oncology
Tasigna 1,529 21% Oncology
Exforge 1,396 -4% Primary care
Galvus 1,224 2% Primary care
Exelon/Exelon Patch 1,009 -2% Neuroscience
Exjade 926 4% Oncology
Xolair 7771 27% Primary Care
Sandimmum / Neoral 684 -9% Integrated Hospital Care
Voltaren (excl. other divisions) 632 (excl. other divisions) -6% Established medicines
Myfortic 543 -15% Integrated Hospital Care
Ritalin/Focalin 492 -17% Established medicines
Femara 380 -1% Oncology
Comtan/Stalevo 371 -7% Neuroscience
Tegretol 346 1% Established medicines
Zortress/Certican 327 31% Integrated Hospital Care

1. Net sales reflect Xolair sales for all indications

Stock chart
Q1 Results 2015

On Thursday, April 23, Novartis will announce its results for the first quarter of 2015